Eli Lilly plans to globally launch its diabetes and weight-loss drug, Mounjaro, in countries including China, India, Brazil, ...

Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, ...

Mounjaro, manufactured by Lilly, may have emerged as the newest and most effective treatment option after a victory over Novo Nordisk’s Ozempic in clinical trials. For some patients, injectables ...

At the 2024 Academy Awards, Eli Lilly, the manufacturer of blockbuster weight loss drugs including Mounjaro and Zepbound, criticized people for taking GLP-1s without an obesity diagnosis.

Lilly reported earlier this month that its revenue in the latest fiscal quarter jumped 45% with its new products contributing more than $3.1 billion, driven mainly by strong demand for Mounjaro ...

In February last year, CEO David Ricks told Reuters that Lilly expects to launch Mounjaro in India as early as 2025. Mounjaro, chemically known as tirzepatide, is currently sold in the UK and ...

The move follows a similar price reduction by competitor Eli Lilly for its weight-loss drug Mounjaro. Less than two weeks after Zepbound-maker Eli Lilly reduced the price of the weight-loss drug ...

David Ricks, the CEO of Mounjaro and Zepbound maker Eli Lilly, explained why these medications are so expensive on the "In Good Company with Nicolai Tangen" podcast this week. Developing a new ...

Of course, Lilly's most important new products are diabetes treatment Mounjaro and weight management medicine Zepbound, which share the active ingredient tirzepatide. In 2024, Eli Lilly's revenue ...